Get started
Author

Deepak L. Bhatt

Observed names: D L Bhatt, DeepakL. Bhatt
OpenAlex ID: A5109991368
Management of Acute Coronary Syndrome in Diabetes Mellitus
2004 · JimM. John, DeepakL. Bhatt · Herz · 8
Contemporary heart failure and mortality burden after STEMI: insights from a real-world cohort
2026 · R Aggarwal, R Kim, et al. · European Heart Journal
PDF
Peak high-sensitivity troponin-T concentration and risk of heart failure in patients with suspected acute coronary syndrome
2026 · P Ahle Erichsen, M Afzal, et al. · European Heart Journal
PDF
Risk of major adverse cardiovascular events after RSV-related hospitalization among US adults with heart failure
2026 · D Singer, A Wu, et al. · European Heart Journal
PDF
Effects of icosapent ethyl on coagulation biomarkers and their association with event-free survival in high-risk cardiovascular patients: a post hoc analysis of the REDUCE-IT
2026 · A Kuenzli, A Tirandi, et al. · European Heart Journal
PDF
High-sensitivity troponin-T concentrations and risk of heart failure in patients with acute pulmonary embolism
2026 · C Byrne, M Afzal, et al. · European Heart Journal
PDF
Benefits of sotagliflozin across the full range of baseline blood pressure in the SOLOIST-WHF Trial
2026 · E Zitelny, D L Bhatt, et al. · European Heart Journal
PDF
Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial
2026 · G G Schwartz, M Szarek, et al. · European Heart Journal
PDF
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
2026 · M Szarek, D L Bhatt, et al. · European Heart Journal
PDF
Artificial intelligence for automated baseline cardiovascular condition identification: accuracy, confidence, and discordance
2026 · R Aggarwal, A Rodman, et al. · European Heart Journal
PDF
Adherence and legacy effects of high dose eicosapentaenoic acid in hypertriglyceridemia and high CV risk – REDUCE-IT Legacy
2026 · C Packard, P G Steg, et al. · European Heart Journal
PDF
First plus recurrent major adverse cardiovascular events with tirzepatide in patients with type 2 diabetes at high cardiovascular risk from SURPASS CVOT
2026 · D L Bhatt, A R Soares, et al. · European Heart Journal
PDF
Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial
2026 · P Steg, M S Szarek, et al. · European Heart Journal
PDF
Sex differences in early study discontinuation and study drug withdrawal: insights from REDUCE-IT
2026 · M F Van Der Bijl, D L Bhatt, et al. · European Heart Journal
PDF
Eicosapentaenoic acid (EPA) limits rapid oxidation of lipoprotein(a) [Lp(a)] yielding favorable changes in endothelial cell protein expression that may contribute to clinical benefits
2026 · S Sherratt, P Libby, et al. · European Heart Journal
PDF
Variability in lipoprotein(a) measurements in ODYSSEY OUTCOMES: is one-and-done testing sufficient?
2026 · M Szarek, P G Steg, et al. · European Heart Journal
PDF
Unsupervised machine-learning identifies cardio-kidney-metabolic phenotypes and determines residual risk after acute coronary syndromes
2026 · Y Wang, M Zeller, et al. · European Heart Journal
PDF
Risk of herpes zoster in patients with cardiovascular diseases: a systematic literature review and meta-analysis
2026 · D L Bhatt, C Williams, et al. · European Heart Journal
PDF
Works count: 18
Citation count: 8
H-index: 1
I10-index:
Year
Topic
Type